High expression of MRPL52 can be used as a prognostic marker of hepatocellular carcinoma and is related to immune infiltration

[1]  Zhonghua Wu,et al.  HIF-1-induced mitochondrial ribosome protein L52: a mechanism for breast cancer cellular adaptation and metastatic initiation in response to hypoxia , 2021, Theranostics.

[2]  Yonglong Chen,et al.  Prefoldin subunit MM1 promotes cell migration via facilitating filopodia formation. , 2020, Biochemical and biophysical research communications.

[3]  Zhiping Hu,et al.  CRISPR/Cas9‐mediated whole genomic wide knockout screening identifies mitochondrial ribosomal proteins involving in oxygen‐glucose deprivation/reperfusion resistance , 2020, Journal of cellular and molecular medicine.

[4]  S. Chávez,et al.  Overexpression of Canonical Prefoldin Associates with the Risk of Mortality and Metastasis in Non-Small Cell Lung Cancer , 2020, Cancers.

[5]  Y. Kim,et al.  Tumor immune microenvironment in cancer patients with leukocytosis , 2020, Cancer Immunology, Immunotherapy.

[6]  Guoan Chen,et al.  Effective targeting of the ubiquitin-like modifier NEDD8 for lung adenocarcinoma treatment , 2020, Cell Biology and Toxicology.

[7]  T. Aittokallio,et al.  DNMT Inhibitors Increase Methylation in the Cancer Genome , 2019, Front. Pharmacol..

[8]  A. Villanueva.  Hepatocellular Carcinoma. , 2019, The New England journal of medicine.

[9]  B. Győrffy,et al.  Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma , 2018, Royal Society Open Science.

[10]  H. Hatano,et al.  Prognostic impact of the tumor immune microenvironment in synovial sarcoma , 2018, Cancer science.

[11]  Lei Chen,et al.  HCCDB: A Database of Hepatocellular Carcinoma Expression Atlas , 2018, Genom. Proteom. Bioinform..

[12]  P. Schirmacher,et al.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.

[13]  Jing Wang,et al.  LinkedOmics: analyzing multi-omics data within and across 32 cancer types , 2017, Nucleic Acids Res..

[14]  Jun S. Liu,et al.  TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. , 2017, Cancer research.

[15]  Alan D. Lopez,et al.  The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level , 2017, JAMA oncology.

[16]  Chad J. Creighton,et al.  UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses , 2017, Neoplasia.

[17]  A. Barrientos,et al.  Mitochondrial ribosomes in cancer. , 2017, Seminars in cancer biology.

[18]  Bin Zhang,et al.  DiseaseMeth version 2.0: a major expansion and update of the human disease methylation database , 2016, Nucleic Acids Res..

[19]  Nurul Ainin Abdul Aziz,et al.  A 19-Gene expression signature as a predictor of survival in colorectal cancer , 2016, BMC Medical Genomics.

[20]  B. Graubard,et al.  Population attributable fractions of risk factors for hepatocellular carcinoma in the United States , 2016, Cancer.

[21]  A. Koch,et al.  MEXPRESS: visualizing expression, DNA methylation and clinical TCGA data , 2015, BMC Genomics.

[22]  Nobhojit Roy,et al.  The Global Burden of Cancer 2013. , 2015, JAMA oncology.

[23]  Antoni Ribas,et al.  Tumor immunotherapy directed at PD-1. , 2012, The New England journal of medicine.

[24]  L. Coussens,et al.  Immune microenvironments in solid tumors: new targets for therapy. , 2011, Genes & development.

[25]  Yasuhiko Sugawara,et al.  Hepatocellular Carcinoma: Current Management and Future Development—Improved Outcomes with Surgical Resection , 2011, International journal of hepatology.

[26]  David Warde-Farley,et al.  GeneMANIA: a real-time multiple association network integration algorithm for predicting gene function , 2008, Genome Biology.

[27]  Francesco Donato,et al.  Hepatocellular carcinoma in cirrhosis: incidence and risk factors. , 2004, Gastroenterology.

[28]  Zhao-You Tang,et al.  Randomized controlled trial of screening for hepatocellular carcinoma , 2004, Journal of Cancer Research and Clinical Oncology.

[29]  E. Yeh,et al.  Characterization of NEDD8, a Developmentally Down-regulated Ubiquitin-like Protein* , 1997, The Journal of Biological Chemistry.

[30]  K. Bichler,et al.  Immune status and immune therapy of renal cell carcinoma. , 1990, Urologia internationalis.